Tag Archives: Blood Treatment

“Superblood” Engineered to Carry Cancer Fighting Proteins

"Superblood" Engineered to Carry Cancer Fighting Proteins
“Superblood” Engineered to Carry Cancer Fighting Proteins

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood” as a revolutionary new cancer treatment.

“Supercharging” Red Blood Cells

Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells that are genetically engineered to fight cancer. Once introduced into a patient’s system, these proteins can replace missing enzymes and help the immune system attack and destroy cancer cells.

RCT has two major advantages that make it a promising breakthrough in cancer treatment:

– The nuclei have been removed from these cells so they can’t be recognized by the immune system, leaving them free from interference so they can do their job.

– Red blood cells travel throughout the entire body, so RCT is able to easily reach any affected organs or tissues.

Thanks to these two features, RCT has the potential to treat patients without the need for an individually developed solution.

What’s Next?

Initially, Rubius Therapeutics generated $120 million from investors. The company recently raised an additional $100 million for a total of nearly a quarter of a billion dollars in less than one year. According to Rubius president Torben Straight Nissen, this funding will help accelerate RCT development for quicker delivery to the end users.

IsselsĀ®: The Leader in Immunotherapy Cancer Treatments

Much like RCT, cancer treatment at IsselsĀ® is designed to boost the immune system’s ability to attack and kill cancer cells. Contact us to learn more about cancer vaccines and other programs we have used to help patients achieve long-term remission.

New Developments in Treatment for Blood Cancer Drug Resistance

New Blood Treatment
New Blood Treatment

Recently you may have seen some promising cancer research in the news concerning treatment for blood cancer drug resistance. Scientists at the University of Southampton have developed a drug that has the potential to reverse this resistance. Preliminary testing has shown great promise and may potentially be used for patients that have certain types of leukemia and lymphoma. These drugs are made from chemically engineered immune proteins that are considered to be antibodies. As these antibodies stick to the proteins on cancer cells, the immune system is directed to kill the cancer cells.

The reason these new drugs are working for people who have experienced resistance is that many of these drugs can be developed to prevent cancer cells from being able to hide from the immune cells, according to a study published in the Cancer Cell journal. This research was done by scientists located at the University of Southampton as well as professionals at BioInvent International. These studies were funded by the Leukemia and Lymphoma Research Foundation in the UK.

A new antibody that is called BI-1206, has also been discovered and it can prevent tolerance by binding to a certain molecule that is called FcyRIIB; this allows for cancer cells to be destroyed. A six year plan is being put into place by a team of professors and scientists in Southampton and Sweden to build on this exciting research. With more information and newly developed treatment options, blood cancer drug resistance may see great changes in the near future.

At Issels we want to help you stay abreast of cancer research news. For more breaking news please subscribe to our weekly newsletter.